In conclusion, based on our experience we suggest considering LB for patients who have not had TB or have insufficient tissue to determine the presence of KRAS/NRAS/BRAF mutations, especially in the context of high tumor burden prior to therapy. This evidence concerns the gene KRAS and tuberculosis.